Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold?

Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below.

Comparing STEP 1 (N Engl J Med, 2021) with SURMOUNT-1 (N Engl J Med, 2022) and finding the comparison harder than it looks.

Different populations, different durations, different endpoints defined slightly differently, and in one case a different estimand. People compare the headline percentages anyway, including me until recently.

Is there a defensible way to put these side by side, or is the honest answer that there is not and we should stop?

SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological endpoint. Notable because soft endpoints are avoided. Two parallel trials addressed the confounder directly.

Picking up the opening post: that is the part I would want checked first.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.